NewAmsterdam Pharma Company N.V.
NAMS
$35.26
-$0.59-1.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.91% | 762.15% | 586.97% | 223.37% | 78.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.91% | 762.15% | 586.97% | 223.37% | 78.77% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 4.91% | 762.15% | 586.97% | 223.37% | 78.77% |
| SG&A Expenses | 66.95% | 85.49% | 88.86% | 87.19% | 85.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.39% | 9.57% | 15.29% | 12.58% | 21.80% |
| Operating Income | -10.21% | 17.20% | 4.46% | 3.65% | -15.11% |
| Income Before Tax | -11.15% | 27.75% | 18.06% | -36.57% | -20.19% |
| Income Tax Expenses | -100.00% | -103.70% | -103.70% | -103.70% | -- |
| Earnings from Continuing Operations | -11.14% | 27.76% | 18.07% | -36.54% | -20.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.14% | 27.76% | 18.07% | -36.54% | -20.20% |
| EBIT | -10.21% | 17.20% | 4.46% | 3.65% | -15.11% |
| EBITDA | -10.14% | 17.26% | 4.51% | 3.69% | -15.09% |
| EPS Basic | 10.21% | 39.89% | 31.27% | -19.63% | 90.74% |
| Normalized Basic EPS | 8.65% | 43.62% | 32.84% | -10.88% | 91.00% |
| EPS Diluted | 10.21% | 39.89% | 31.27% | -19.63% | 90.75% |
| Normalized Diluted EPS | 8.65% | 43.62% | 32.84% | -10.88% | 91.00% |
| Average Basic Shares Outstanding | 25.75% | 23.23% | 20.76% | 14.80% | 45.38% |
| Average Diluted Shares Outstanding | 25.75% | 23.23% | 20.76% | 14.80% | 45.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |